Pioneering Regenerative Medicine
Without Immunosuppression
Pioneering Regenerative Medicine
Without Immunosuppression
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
Developing a Potential Cure for Type 1 Diabetes
Our lead program iTOL-102 combines our iTOL-100 technology with an inexhaustible supply of insulin producing allogeneic stem cell-derived pancreatic islets and is being developed as a potential cure for Type 1 Diabetes. In a pre-clinical non-human primate study, allogenic pancreatic islet cells co-implanted with SA-FasL microgel exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression.
Development Pipeline
We Were 1 of 3 Companies Selected to Participate in the
Disruptive Healthcare Technology Showcase at the US Capital
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
BioFlorida Announces Appointment of Dr. Anthony Japour, CEO of iTolerance, Inc., as Chair of the Southeast Chapter
MIAMI, Dec. 22, 2025 /PRNewswire/ -- BioFlorida, Inc. ("BioFlorida"), Florida's preeminent life sciences association, is excited to announce the appointment of Anthony Japour, CEO of iTolerance, Inc. ("iTolerance"), as Southeast Chapter Chair, effective December 15,...
iTolerance, Inc. Releases Next Video in Its Patient Journey Series Highlighting the Real-Life Impact of Type 1 Diabetes
Watch the next video segment here MIAMI, FL / ACCESS Newswire / December 3, 2025 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced...
iTolerance CEO, Anthony Japour, Receives BioFlorida’s Research & Developer of the Year Award
MIAMI, FL / ACCESS Newswire / November 12, 2025 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced that Anthony Japour, Chief...